Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• TP53 gene mutations are frequent in human cancers, leading to both loss of tumor suppressor function and gain of oncogenic functions (GOF).
• Evidence suggests varying GOF effects among different p53 hotspot mutations, primarily from cellular and animal models.

Purpose of the Study:

• To investigate the prognostic significance of distinct p53 mutations in human cancers using large-scale genomic data.
• To explore the functional consequences of specific p53 mutations, particularly their association with drug metabolism and chemosensitivity.

Main Methods:

• Analysis of large-scale human cancer genomic data to correlate p53 mutation status with patient survival.
• Gene set enrichment analysis to identify pathways affected by specific p53 mutations.
• In vitro experiments involving ectopic expression of p53 mutants and assessment of CYP3A4 levels and drug resistance.

Main Results:

• Mutations at p53 positions Arg248 and Arg282 were significantly associated with shorter patient survival, unlike other hotspot GOF mutations.
• These specific mutations correlated with increased activity of drug-metabolizing enzymes, notably CYP3A4.
• Ectopic expression of p53 R282W mutant increased CYP3A4 expression, and cancer cells with mortality-associated p53 mutations showed higher CYP3A4 levels and resistance to CYP3A4-metabolized drugs.

Conclusions:

• p53 mutations exhibit differential gain-of-function activities and prognostic impacts in human cancers.
• The specific p53 mutation type, not just wild-type versus mutant status, is crucial for evaluating its role as a cancer biomarker.
• Targeting pathways like CYP3A4 may offer therapeutic strategies for cancers with specific p53 mutations.